It is a Saturday, so this is the story of how October ended on Friday — and it ended rough. Counting down the three stories that did the damage, from three to one.
Number three: Binance put a number and a clock on the hack
Binance put a number and a clock on the biggest crypto theft on record. The exchange said it has set aside more than $6.34 billion of its own money to cover the roughly $6.3 billion stolen from its hot wallets — $5 billion of it already held in the same tokens that were taken, about 80% covered, with the rest being bought. About $3 billion of the stolen assets have been frozen with partners' help. Withdrawals are still paused, but Binance is targeting a phased restart within roughly 34 hours of its Friday update, so sometime this weekend, with a full proof of reserves promised by Monday, November 2. Blockchain firms TRM Labs and Chainalysis link the attack, with high confidence, to North Korea's TraderTraitor group, and TRM estimates the attacker still holds about $2.4 billion in Bitcoin and Ether that no issuer can freeze. That is the part to watch this weekend: withdrawals either come back, or they don't.
Number two: oil up, gold down — both big
Oil went one way and gold went the other, and both moves were big. A tanker in the Strait of Hormuz was hit by explosive devices attached from a small boat — maritime sources called it the first successful limpet-mine strike in the strait since the war began — and Brent's December contract expired up 2.4% at $117.64, the January contract settled at $113.43, and WTI rose 2.08% to $104.12. That caps a 13.6% October for Brent and 15.2% for WTI, a fourth straight monthly gain, to the highest levels since late April. Gold did the opposite of what a war headline is supposed to do: it fell about 3.5% to around $3,880 an ounce, its lowest in a year, roughly 30% below its January record, because hot inflation and December Fed hike bets make a no-yield asset expensive to hold while rates climb. When even the safe haven gets sold, that tells you the selling was about rates, not just fear.
Number one: Intel's worst day in 52 years
Intel had its worst day in 52 years, and it took the whole tech complex with it. Intel plunged 28.58% to $65.76 after guiding fourth-quarter revenue to $15–16 billion against $17.07 billion expected. The Nasdaq fell 2.86% to 25,437 — its worst day since June — the S&P 500 fell 1.82% to 7,580, and the Dow fell 1.09% to 51,770. The Nasdaq closed October down about 5.2%, its worst month since March 2025, and the Nasdaq 100 fell 3.46% into correction territory. Amazon fell only 1.41%, but the reason matters more than the size: AWS grew 39% to about $46 billion, and investors still sold it, because trailing free cash flow is negative $42.4 billion and the roughly $220 billion spending forecast stayed put. The market is not doubting AI demand anymore. It is doubting the bill.
What it did to the tape
Crypto steadied without recovering. Bitcoin closed the Friday UTC day at $77,160, down 0.8%, Ether at $2,241, down 0.4%, total market cap at about $2.61 trillion, and Fear and Greed held at 30, Fear — unchanged, which after a week like this almost counts as calm. Six S&P sectors actually rose Friday while tech fell over 4%; this was a tech-and-rates selloff, not everything-at-once panic.
The earnings desk
Friday's prints were the split in one day. Chevron beat: adjusted $5.28 against $4.89 expected, the stock up about 1.8%. Exxon beat too: adjusted $4.23, revenue up 32.7% to $113.16 billion, the stock up about 2.2% — plus a 4-cent dividend raise to $1.07 a share, payable December 10, and a $20 billion buyback planned for 2027. Refining money, paid out like clockwork. AbbVie beat at $3.82 against $3.75 and raised full-year guidance. Colgate beat at 97 cents against 93 cents expected, sales up 4.6% to $5.37 billion, raised its margin and earnings guidance, and rose 2.29%. And the day's blowout was Regeneron: adjusted earnings of $20.07 against roughly $16.24 expected, revenue up 36% to $5.12 billion on record Dupixent, Eylea HD, and Libtayo sales — the stock surged 13.33%.
Nothing reports today, it is a Saturday. Next up, Monday after the close: Apple, expected at $1.99 a share on about $113.4 billion in revenue, judged on iPhone demand and whether services can carry the AI-spending mood; and Palantir, expected at 41 cents on about $2.18 billion, judged on commercial AI growth against a valuation near 87 times forward earnings — after this week, a good print may not be enough if the guide blinks.
Invention spotlight: a DNA shot instead of the operating room
On October 30, the FDA granted accelerated approval to INOVIO's Voceryq — the first plasmid DNA-based immunotherapy ever approved in the United States, and INOVIO's first approved product. It treats recurrent respiratory papillomatosis, a rare disease where HPV types 6 and 11 grow wart-like tumors in the airways, and patients have historically just had them surgically cut out, over and over, sometimes for years. Voceryq instead delivers two small pieces of DNA — one teaching the immune system to recognise the HPV proteins, one adding interleukin-12 to strengthen the response — injected with a device that uses brief electrical pulses to get the DNA into cells. In the 32-patient study behind the approval, every patient had needed at least two surgeries in the prior year, and the approval rests on patients going twelve months with no surgery at all. It is accelerated approval, so a confirmatory study still has to prove the benefit holds, and INOVIO expects it to be orderable in about 60 days. Fewer trips to the operating room for people who have already had too many — that is the whole story, and it is a good one.
The oversold corner
The screen ran 127 assets — large caps, midcaps, microcaps, and top cryptos, from Yahoo Finance and CoinGecko daily closes — and 26 meet all three tests: RSI at or below 35, MACD bearish, and price below the 90-day average. The five most oversold: Alphabet at $279.84, RSI 21.4, 18.7% below its average — still sliding two days after that earnings wipeout. Intel at $65.76, RSI 25.1, 35.9% below — a 52-year worst day does that to a chart. Cipher Mining (CIFR) at $7.29, RSI 25.4, and 57.1% below its 90-day average — miners are getting sold on the Bitcoin and Binance headlines twice removed. Fortinet at $136.08, RSI 26.6, 17.8% below, still falling after its earnings dive. And ServiceNow at $105.12, RSI 26.9, 16.8% below, still paying for that one-cent miss and soft guide. Oversold is a description, not a buy idea.
The BogusAPY angle
Two hooks. First, Binance is now a live audit you can grade in real time: $6.34 billion set aside, $5 billion already in the exact tokens taken, proof of reserves promised by Monday, withdrawals promised this weekend. Any platform can advertise a yield or a safety fund. Binance just showed what the claim looks like when it has to be proven — a number, a deadline, and a public report. That is the script: grade every platform's promise the same way, against what it publishes when it is bleeding.
Second, the quiet DeFi footnote: Aave briefly blocked new deposits and borrowing after the attacker borrowed Ether against stolen tokens, then reopened October 30 with nine assets barred as collateral. Even a lending yield that looks clean inherits the hack the moment stolen collateral walks in the door. Where does the yield come from is only half the question. The other half is whose mess it is standing next to.
Get posts like this by email: Subscribe to BogusAPY
Sources: Reuters via CNBC and market wraps (Oct 30 index closes, Intel -28.58%, oil settlements and October gains, UKMTO Hormuz attack), AP (Intel steepest drop since 1974), Forbes and CoinDesk (Binance $6.34B reserve, phased withdrawal restart, proof of reserves by Nov 2), TRM Labs via Forbes/Reuters (TraderTraitor attribution, ~$2.4B unfrozen), Kitco/Reuters (gold ~-3.5% to one-year low), Basis Desk / CoinGecko (BTC $77,160 -0.8%, ETH $2,241 -0.4%, total cap $2.61T, Fear & Greed 30), company reports via Reuters/Finnhub (Chevron, Exxon, AbbVie, Colgate, Regeneron), FactSet/IBD and Zacks (Apple $1.99 / Palantir $0.41 expectations for Mon Nov 2), FDA and INOVIO (Voceryq accelerated approval, Oct 30), Winbuzzer (Aave collateral restrictions), Yahoo Finance and CoinGecko (screener, 127 assets). Not financial advice.
Comments
Post a Comment